StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) stock

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$15.29−2.21 (-12.66%)

Close on Nov 18, 2026Market cap $83.97MP/E –Yield –

InMed Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

InMed Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2024 was -$7.00M. For fiscal 2024 it was -$7.00M. The highest annual figure on record is -$7.00M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Jun 30, 2024-$7.00M–
FY2023Jun 30, 2023-$7.44M–
FY2022Jun 30, 2022-$15.62M–
FY2021Jun 30, 2021-$9.79M–
FY2020Jun 30, 2020-$7.42M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2024CQ2 2024Jun 30, 2024-$1.03M–
Q3 FY2024CQ1 2024Mar 31, 2024-$1.93M–
Q4 FY2023CQ2 2023Jun 30, 2023-$689.75K–
Q4 FY2022CQ2 2022Jun 30, 2022-$4.05M–
Q3 FY2022CQ1 2022Mar 31, 2022-$5.35M–
Q2 FY2022CQ4 2021Dec 31, 2021-$3.32M–
Q1 FY2022CQ3 2021Sep 30, 2021-$2.90M–
Q4 FY2020CQ2 2020Jun 30, 2020-$1.40M–
Q3 FY2020CQ1 2020Mar 31, 2020-$1.53M–
Q2 FY2020CQ4 2019Dec 31, 2019-$2.09M–
Q1 FY2020CQ3 2019Sep 30, 2019-$2.40M–

More InMed Pharmaceuticals figures

See a number that looks wrong?